Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
December 4, 2018
Theravance Biopharma to Highlight Innovative Early Research and Clinical Development at R&D Day on December 12 in New York
DUBLIN, Dec. 4, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") will host an R&D Day from 12:00 p.m. ET to 3:00 p.m. ...
December 4, 2018
Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting
WATERTOWN, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and ...
December 4, 2018
Inspire Medical Systems, Inc. Announces Proposed Offering of Common Stock
MINNEAPOLIS, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:  INSP) (“Inspire”), a medical technology company focused on the development and commercialization of ...
December 4, 2018
VALNEVA to Conduct Investor and Partnering Meetings During the 37th Annual J.P. Morgan Healthcare Conference
Saint-Herblain (France), December 4, 2018 - Valneva SE ("Valneva"), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today ...
December 3, 2018
Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030
BOSTON, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today ...
December 3, 2018
Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer
PALO ALTO, Calif., Dec. 3, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare ...
December 3, 2018
INNATE PHARMA : Updated results that support advancement of IPH4102 in refractory Sézary syndrome at ASH 2018
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), today announced updated data from the Phase I trial (including an expansion cohort) evaluating ...
December 3, 2018
miRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase 1 Cobomarsen Clinical Trial in Patients With Mycosis Fungoides
BOULDER, Colo., Dec. 02, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, ...
December 3, 2018
ArQule Announces Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2018 ASH Annual Meeting
ArQule, Inc. (ARQL) yesterday presented preliminary results from the Company’s Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor ...
December 3, 2018
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
VANCOUVER , Dec. 3, 2018 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of ...
December 3, 2018
RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 03, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
December 3, 2018
Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting
SAN DIEGO and TORONTO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the presentation of preclinical data from ...
December 3, 2018
Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies
PALO ALTO, Calif., Dec. 3, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare ...
December 3, 2018
Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update
LIVONIA, Mich., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
December 3, 2018
Theravance Biopharma Announces Closing of Private Placement of $250 Million of 9% Non-Recourse Notes
DUBLIN, Dec. 3, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" and together with its subsidiaries, the "Company") today announced the closing of a private ...
December 3, 2018
Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA® (ZX008) in Dravet Syndrome
EMERYVILLE, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) --  Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare diseases, announced today that ...
December 3, 2018
Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study
NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (EYEN) today announced that it has completed patient enrollment in its Phase III MIST-1 study ...
December 3, 2018
Mainstay Medical to Showcase ReActiv8 and Key Clinical Data at the 13th German Spine Congress of the DWG
DUBLIN--(BUSINESS WIRE)--Regulatory News: Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on commercializing ReActiv8®, ...
November 29, 2018
TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs
SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
November 29, 2018
ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies
BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (ARQL) today announced that it will host a call to discuss the updated safety, PK, biomarker and anti-tumor activity data from ...
Page 2 of 117